Ruxolitinib Zentiva (ruxolitinib)

Where it stands

Ruxolitinib Zentiva (ruxolitinib), from Zentiva k.s., is authorised in the EU. The CHMP adopted a positive opinion on 17 September 2026, and the European Commission decision granting the marketing authorisation followed on 12 November 2026. Both milestones are recorded as official, and the records list no other milestones.

The authorisation covers three indication groups. First, myelofibrosis: disease-related splenomegaly or symptoms in adults with primary myelofibrosis, post-polycythaemia vera myelofibrosis or post-essential thrombocythaemia myelofibrosis. Second, polycythaemia vera: adults who are resistant to or intolerant of hydroxyurea. Third, graft versus host disease (GvHD).

The GvHD wording is split by age. Acute GvHD is covered in adults and paediatric patients aged 28 days and older. Chronic GvHD is covered in adults and paediatric patients aged 6 months and older. In both, patients must have had an inadequate response to corticosteroids or other systemic therapies. The records do not say whether the product has been launched.

Regulatory pathway and designations

The only designation recorded is "Generic". This means the product was authorised as a generic medicine, not through a full stand-alone application. In general, a generic relies on an existing reference product and must show it is comparable to it. The records do not name the reference product, the legal basis or the procedure type, so I do not state them here.

The interval between the CHMP opinion and the EC decision was about eight weeks. This is the usual step in the centralised procedure, where the Commission converts the CHMP opinion into a binding decision for the EU. The records give no detail on conditions, post-authorisation obligations or any exceptional-circumstances status.

Several products with the same substance are listed. Jakavi (EU, Authorised), Ruxolitinib Viatris (EU, Authorised) and Opzelura (EU, Authorised) are already authorised. Ruxolitinib Krka (EU) is at the opinion stage. Jakafi Xr (US) is approved. The records give no indications, formulations or relationships for these products, so I draw no comparisons. They show only that the substance already has a multi-product presence in the EU, with at least one more generic opinion in the pipeline.

Safety and pharmacovigilance

The records contain no safety data. They include no adverse-event profile, no risk management plan details, no additional risk minimisation measures and no post-marketing commitments, so I make no safety statements about this product.

As a general principle, a generic's product information is expected to be consistent with that of its reference medicine, and authorised products stay under routine EU pharmacovigilance after approval. Readers who need the specifics should check the approved product information (SmPC and package leaflet) and any RMP published with the EC decision.

What to watch

Ruxolitinib Krka is listed at the opinion stage in the EU. If it receives an EC decision, it would add to the number of authorised ruxolitinib products alongside Jakavi and the Viatris and Zentiva generics. The records give no timing for this.

The records do not cover national launch timing, pricing, reimbursement or any supply or litigation matters, and I do not speculate on them. For a professional audience, the practical next checks are the published EPAR or product information, the Union Register entry and the member-state launch notifications.